DK2718282T3 - Farmaceutisk sammensætning, som omfatter et amidderivat, der hæmmer væksten af cancerceller, og et smøremiddel uden metalsalt - Google Patents
Farmaceutisk sammensætning, som omfatter et amidderivat, der hæmmer væksten af cancerceller, og et smøremiddel uden metalsalt Download PDFInfo
- Publication number
- DK2718282T3 DK2718282T3 DK12796126.6T DK12796126T DK2718282T3 DK 2718282 T3 DK2718282 T3 DK 2718282T3 DK 12796126 T DK12796126 T DK 12796126T DK 2718282 T3 DK2718282 T3 DK 2718282T3
- Authority
- DK
- Denmark
- Prior art keywords
- pharmaceutical composition
- lubricant
- compound
- coating substrate
- metal salt
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
- A61K9/204—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/52—Esters of acyclic unsaturated carboxylic acids having the esterified carboxyl group bound to an acyclic carbon atom
- C07C69/604—Polycarboxylic acid esters, the acid moiety containing more than two carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Inorganic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Charge And Discharge Circuits For Batteries Or The Like (AREA)
Claims (15)
1. Farmaceutisk sammensætning, som omfatter en forbindelse med formlen (I) eller et farmaceutisk acceptabelt salt deraf; og et smøremiddel valgt blandt smøremiddel uden metal, hvor smøremidlet uden metalsalt er valgt fra gruppen bestående af fedtsyreestere, fedtsyrer, olier, polyethylenglycoler (PEG'er), stivelse, talkum og en blanding deraf
2. Farmaceutisk sammensætning ifølge krav 1, hvor smøremidlet uden metalsalt er valgt fra gruppen bestående af glycerylbehenat, glycerylpalmitostearat, glycerylmonostearat, glyceryltrimyristat, glyceryltristearat, saccharose-fedtsyreester, palmitinsyre, stearinsyre, alkohol, hydrogeneret ricinusolie, mineralolie, hydrogeneret vegetabilsk olie, PEG 4000, PEG 6000 og en blanding deraf.
3. Farmaceutisk sammensætning ifølge krav 2, hvor smøremidlet uden metalsalt er saccharose-fedtsyreester eller hydrogeneret vegetabilsk olie.
4. Farmaceutisk sammensætning ifølge krav 1, hvor forbindelsen med formlen (I) er indeholdt i en mængde i intervallet fra 0,1 mg til 100 mg pr. 1 doseringsenhed af sammensætningen.
5. Farmaceutisk sammensætning ifølge krav 1, hvor smøremidlet uden metalsalt er indeholdt i en mængde i intervallet fra 0,1 til 100 vægtdele baseret på 1 vægtdel af forbindelsen med formlen (I).
6. Farmaceutisk sammensætning ifølge krav 1, som yderligere omfatter et farmaceutisk acceptabelt tilsætningsstof valgt fra gruppen bestående af et fortyndingsmiddel, et bindemiddel, et desintegrationsmiddel og en blanding deraf.
7. Farmaceutisk sammensætning ifølge krav 6, hvor fortyndingsmidlet er indeholdt i en mængde i intervallet fra 20 til 95 vægtprocent baseret på den samlede vægt af sammensætningen.
8. Farmaceutisk sammensætning ifølge krav 6, hvor bindemidlet er indeholdt i en mængde i intervallet fra 1 til 10 vægtprocent baseret på den samlede vægt af sammensætningen.
9. Farmaceutisk sammensætning ifølge krav 6, hvor desintegrationsmidlet er indeholdt i en mængde i intervallet fra 1 til 30 vægtprocent baseret på den samlede vægt af sammensætningen.
10. Farmaceutisk sammensætning ifølge krav 1, som er overtrukket med et overtrækssubstrat valgt fra gruppen bestående af et overtrækssubstrat til hurtig frigivelse, et enterisk overtrækssubstrat og et overtrækssubstrat til langvarig frigivelse.
11. Farmaceutisk sammensætning ifølge krav 10, hvor overtrækssubstratet er valgt fra gruppen bestående af hydroxypropylcellulose, hydroxypropylmethylcellulose, polyvinylalkohol, polyvinylalkohol-polyethylenglycol-graftcopolymer, (meth)acrylsyrecopolymer, phthalsyrehydroxypropylmethylcellulose, phthalsyrecelluloseacetat, celluloseacetat, ethylcellulose, polyvinylacetat og en blanding deraf.
12. Farmaceutisk sammensætning ifølge krav 1, som omfatter mindre end 0,5 vægtprocent af en forbindelse med formlen (II) under ekstreme betingelser, opbevaret i en lufttæt HDPE-beholder ved 60°C i 4 uger, eller under accelererede betingelser, opbevaret i en lufttæt HDPE-beholder ved 40°C og 75% RH i 6 måneder:
13. Fremgangsmåde til fremstilling afen formulering af den farmaceutiske sammensætning ifølge krav 1, hvilken fremgangsmåde omfatter følgende trin: (1) at blande en forbindelse med formlen (I) eller et farmaceutisk acceptabelt salt deraf med et farmaceutisk acceptabelt tilsætningsstof og granulere blandingen for at opnå et granulat; (2) at blande det i trin (1) fremstillede granulat med et farmaceutisk acceptabelt tilsætningsstof og tilsætte et smøremiddel uden metalsalt dertil for at opnå et blandet granulat; og (3) at underkaste det i trin (2) fremstillede blandede granulat et formuleringstrin
14. Fremgangsmåde ifølge krav 13, som yderligere omfatter trinet at overtrække den i trin (3) fremstillede formulering med et overtrækssubstrat valgt fra gruppen bestående af et overtrækssubstrat til hurtig frigivelse, et enterisk overtrækssubstrat og et overtrækssubstrat til langvarig frigivelse.
15. Fremgangsmåde til stabilisering afen farmaceutisk sammensætning, som omfatter en forbindelse med formlen (I) eller et farmaceutisk acceptabelt salt deraf, hvilken fremgangsmåde omfatter at tilsætte et smøremiddel uden metalsalt til den farmaceutiske sammensætning: hvor smøremidlet uden metalsalt er valgt fra gruppen bestående af fedtsyreestere, fedtsyrer, olier, polyethylenglycoler (PEG'er), stivelse, talkum og en blanding deraf
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020110054685A KR101317809B1 (ko) | 2011-06-07 | 2011-06-07 | 암세포의 성장을 억제하는 아마이드 유도체 및 비금속염 활택제를 포함하는 약학 조성물 |
PCT/KR2012/003970 WO2012169733A1 (en) | 2011-06-07 | 2012-05-18 | Pharmaceutical composition comprising amide derivative inhibiting the growth of cancer cells and non-metallic salt lubricant |
Publications (1)
Publication Number | Publication Date |
---|---|
DK2718282T3 true DK2718282T3 (da) | 2017-05-22 |
Family
ID=47296259
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK12796126.6T DK2718282T3 (da) | 2011-06-07 | 2012-05-18 | Farmaceutisk sammensætning, som omfatter et amidderivat, der hæmmer væksten af cancerceller, og et smøremiddel uden metalsalt |
Country Status (25)
Country | Link |
---|---|
US (2) | US9731022B2 (da) |
EP (1) | EP2718282B1 (da) |
JP (1) | JP6030643B2 (da) |
KR (1) | KR101317809B1 (da) |
CN (1) | CN103596940B (da) |
AR (1) | AR086851A1 (da) |
AU (1) | AU2012267642C1 (da) |
BR (1) | BR112013030456B1 (da) |
CA (2) | CA3053181A1 (da) |
CL (1) | CL2013003513A1 (da) |
CO (1) | CO6852070A2 (da) |
DK (1) | DK2718282T3 (da) |
EC (1) | ECSP14013121A (da) |
ES (1) | ES2625268T3 (da) |
IL (1) | IL229739B (da) |
MA (1) | MA35405B1 (da) |
MX (2) | MX361129B (da) |
MY (1) | MY166949A (da) |
PE (1) | PE20141040A1 (da) |
PT (1) | PT2718282T (da) |
RU (1) | RU2632099C2 (da) |
TW (1) | TWI617307B (da) |
UA (1) | UA112545C2 (da) |
WO (1) | WO2012169733A1 (da) |
ZA (1) | ZA201400051B (da) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101317809B1 (ko) | 2011-06-07 | 2013-10-16 | 한미약품 주식회사 | 암세포의 성장을 억제하는 아마이드 유도체 및 비금속염 활택제를 포함하는 약학 조성물 |
KR20140096571A (ko) * | 2013-01-28 | 2014-08-06 | 한미약품 주식회사 | 1-(4-(4-(3,4-디클로로-2-플루오로페닐아미노)-7-메톡시퀴나졸린-6-일옥시)피페리딘-1-일)프로프-2-엔-1-온의 제조방법 |
EP2878453A1 (de) | 2013-11-28 | 2015-06-03 | Authentic Vision GmbH | Objektmarkierung zur optischen Authentifizierung und Verfahren zu deren Herstellung |
GB201400034D0 (en) | 2014-01-02 | 2014-02-19 | Astrazeneca Ab | Pharmaceutical Compositions comprising AZD9291 |
KR101669240B1 (ko) * | 2015-03-12 | 2016-10-25 | 아주대학교산학협력단 | 테노포비어 디소프록실 유리염기를 포함하는 정제 및 이의 제조방법 |
JP6585193B2 (ja) * | 2015-12-28 | 2019-10-02 | 沢井製薬株式会社 | ゲフィチニブ含有錠剤 |
CN108057036B (zh) * | 2016-11-07 | 2023-06-13 | 正大天晴药业集团股份有限公司 | 一种egfr抑制剂的固体药物组合物 |
PE20191303A1 (es) | 2016-11-17 | 2019-09-23 | Univ Texas | Compuestos con actividad antitumoral contra celulas cancerosas que tienen mutaciones en el exon 20 de egfr o her2 |
US20210361655A1 (en) * | 2018-03-27 | 2021-11-25 | Board Of Regents, The University Of Texas System | Compounds with anti-tumor activity against cancer cells bearing her2 exon 19 mutations |
MX2020012270A (es) | 2018-05-16 | 2021-04-28 | Janssen Biotech Inc | Métodos para tratar cánceres y potenciar la eficacia de agentes terapéuticos para el redireccionamiento de células t. |
MX2021002875A (es) * | 2018-09-14 | 2021-07-15 | Hanmi Pharmaceutical Co Ltd | Formas cristalinas de un compuesto de quinazolina y sus sales clorhidrato. |
WO2020205632A1 (en) * | 2019-03-29 | 2020-10-08 | Board Of Regents, The University Oftexas System | Compounds with anti-tumor activity against cancer cells bearing her2 exon 21 insertions |
KR102254307B1 (ko) * | 2019-04-03 | 2021-05-21 | 위더스제약주식회사 | 보관 안정성이 향상된 에페리손 약제학적 조성물 |
WO2021080375A1 (en) * | 2019-10-24 | 2021-04-29 | Hanmi Pharm. Co., Ltd. | A pharmaceutical preparation comprising an amide derivative inhibiting the growth of cancer cell and a pharmaceutical product containing the same |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH02275891A (ja) * | 1988-12-29 | 1990-11-09 | Tsumura & Co | 新規な複核白金錯体および該錯体を有効成分とする抗腫瘍剤 |
SK282183B6 (sk) * | 1994-08-23 | 2001-11-06 | Smithkline Beecham Plc | Farmaceutický prostriedok |
KR980008219A (ko) | 1996-07-16 | 1998-04-30 | 김상응 | 안정화된 주사제용 약제학적 조성물 |
KR980008219U (ko) | 1996-07-31 | 1998-04-30 | 배순훈 | 세탁기의 구동모터 냉각팬 |
GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
JP3687025B2 (ja) * | 1998-06-04 | 2005-08-24 | 東和薬品株式会社 | 安定なマレイン酸エナラプリル錠剤 |
WO2001021596A1 (en) | 1999-09-21 | 2001-03-29 | Astrazeneca Ab | Quinazoline derivatives and their use as pharmaceuticals |
DE10042061A1 (de) | 2000-08-26 | 2002-03-07 | Boehringer Ingelheim Pharma | Bicyclische Heterocyclen,diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
DE10042058A1 (de) | 2000-08-26 | 2002-03-07 | Boehringer Ingelheim Pharma | Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
IL164167A0 (en) | 2002-03-30 | 2005-12-18 | Boehringer Ingelheim Pharma | 4-(N-phenylamino)-quinazolines/ quinolines as tyrosine kinase inhibitors |
DE602004004811T2 (de) | 2003-09-19 | 2007-11-22 | Astrazeneca Ab | Chinazolinderivate |
GB0322409D0 (en) | 2003-09-25 | 2003-10-29 | Astrazeneca Ab | Quinazoline derivatives |
EP1670786A1 (en) | 2003-09-25 | 2006-06-21 | Astrazeneca AB | Quinazoline derivatives |
DE10345875A1 (de) | 2003-09-30 | 2005-04-21 | Boehringer Ingelheim Pharma | Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Vewendung und Verfahren zu ihrer Herstellung |
AU2005223610B2 (en) | 2004-03-23 | 2008-05-29 | Banyu Pharmaceutical Co., Ltd. | Substituted quinazoline or pyridopyrimidine derivative |
KR20050104152A (ko) | 2004-04-28 | 2005-11-02 | 최승호 | 경구용 약물의 흡수를 증진하는 약제학적 조성물 |
EP1919900A2 (de) | 2005-08-22 | 2008-05-14 | Boehringer Ingelheim International Gmbh | Bicyclische heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung |
KR20080077009A (ko) | 2005-12-12 | 2008-08-20 | 베링거 인겔하임 인터내셔날 게엠베하 | 바이사이클릭 헤테로사이클, 당해 화합물을 함유하는 약제,이의 용도 및 이의 제조방법 |
ES2342965T5 (es) | 2006-04-13 | 2013-04-03 | Acino Pharma Ag | Gliceridos parciales como lubricantes para composiciones farmacéuticas que contienen derviados de tieno(3,2-c)piridina |
TW200812963A (en) | 2006-04-13 | 2008-03-16 | Euro Celtique Sa | Benzenesulfonamide compounds and the use thereof |
TWI377944B (en) | 2007-06-05 | 2012-12-01 | Hanmi Holdings Co Ltd | Novel amide derivative for inhibiting the growth of cancer cells |
MX2009013499A (es) | 2007-06-22 | 2010-01-18 | Bristol Myers Squibb Co | Composiciones comprimidas que contienen atazanavir. |
MY144136A (en) | 2009-04-20 | 2011-08-10 | Univ Sains Malaysia | Throttle and brake lock |
EP2454598B1 (en) * | 2009-07-15 | 2017-03-22 | DiaTech Holdings, Inc. | Drug selection for gastric cancer therapy using antibody-based arrays |
WO2011088149A2 (en) * | 2010-01-12 | 2011-07-21 | Prometheus Laboratories Inc. | Methods for predicting response of triple-negative breast cancer to therapy |
KR101217526B1 (ko) | 2010-06-11 | 2013-01-02 | 한미사이언스 주식회사 | 아마이드 유도체 또는 이의 약학적으로 허용 가능한 염을 포함하는 약제학적 조성물 |
KR101317809B1 (ko) | 2011-06-07 | 2013-10-16 | 한미약품 주식회사 | 암세포의 성장을 억제하는 아마이드 유도체 및 비금속염 활택제를 포함하는 약학 조성물 |
KR101272613B1 (ko) | 2011-10-05 | 2013-06-10 | 한미사이언스 주식회사 | 1-(4-(4-(3,4-디클로로-2-플루오로페닐아미노)-7-메톡시퀴나졸린-6-일옥시)피페리딘-1-일)프로프-2-엔-1-온 염산염의 제조 방법 및 이에 사용되는 중간체 |
-
2011
- 2011-06-07 KR KR1020110054685A patent/KR101317809B1/ko active IP Right Grant
-
2012
- 2012-05-18 JP JP2014514790A patent/JP6030643B2/ja active Active
- 2012-05-18 ES ES12796126.6T patent/ES2625268T3/es active Active
- 2012-05-18 PE PE2013002762A patent/PE20141040A1/es active IP Right Grant
- 2012-05-18 CA CA3053181A patent/CA3053181A1/en active Pending
- 2012-05-18 EP EP12796126.6A patent/EP2718282B1/en active Active
- 2012-05-18 US US14/124,436 patent/US9731022B2/en active Active
- 2012-05-18 MX MX2013013997A patent/MX361129B/es active IP Right Grant
- 2012-05-18 DK DK12796126.6T patent/DK2718282T3/da active
- 2012-05-18 AU AU2012267642A patent/AU2012267642C1/en not_active Ceased
- 2012-05-18 BR BR112013030456-1A patent/BR112013030456B1/pt not_active IP Right Cessation
- 2012-05-18 CN CN201280027500.3A patent/CN103596940B/zh active Active
- 2012-05-18 PT PT127961266T patent/PT2718282T/pt unknown
- 2012-05-18 WO PCT/KR2012/003970 patent/WO2012169733A1/en active Application Filing
- 2012-05-18 UA UAA201315358A patent/UA112545C2/uk unknown
- 2012-05-18 MY MYPI2013004378A patent/MY166949A/en unknown
- 2012-05-18 CA CA2837703A patent/CA2837703C/en active Active
- 2012-05-18 RU RU2013158858A patent/RU2632099C2/ru active
- 2012-06-06 TW TW101120270A patent/TWI617307B/zh active
- 2012-06-07 AR ARP120102013A patent/AR086851A1/es not_active Application Discontinuation
-
2013
- 2013-11-28 MX MX2021005494A patent/MX2021005494A/es unknown
- 2013-12-01 IL IL229739A patent/IL229739B/en active IP Right Grant
- 2013-12-06 CL CL2013003513A patent/CL2013003513A1/es unknown
-
2014
- 2014-01-02 EC ECSP14013121 patent/ECSP14013121A/es unknown
- 2014-01-03 MA MA36642A patent/MA35405B1/fr unknown
- 2014-01-03 CO CO14000880A patent/CO6852070A2/es unknown
- 2014-01-06 ZA ZA2014/00051A patent/ZA201400051B/en unknown
-
2017
- 2017-08-11 US US15/675,666 patent/US9931406B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK2718282T3 (da) | Farmaceutisk sammensætning, som omfatter et amidderivat, der hæmmer væksten af cancerceller, og et smøremiddel uden metalsalt | |
KR101290925B1 (ko) | 코팅된 정제 제형 및 방법 | |
DK2580206T3 (da) | Farmaceutisk sammensætning, som omfatter et amidderivat eller et farmaceutisk acceptabelt salt deraf | |
KR20160101720A (ko) | Azd9291을 포함하는 제약 조성물 | |
KR20140030505A (ko) | 이베살탄 및 HMG-CoA 환원효소 억제제를 포함하는 약제학적 캡슐 복합제제 | |
CN116869915A (zh) | 含有苯并咪唑衍生物的新型制剂 | |
AU2017244982A1 (en) | Film-coated tablet having high chemical stability of active ingredient | |
RU2651460C2 (ru) | Комбинированная композиция, содержащая метформин замедленного высвобождения и ингибитор HMG-CoA-редуктазы немедленного высвобождения | |
JP7370125B2 (ja) | エルロチニブを有効成分とする医薬錠剤 | |
NZ619606B2 (en) | Pharmaceutical composition comprising amide derivative inhibiting the growth of cancer cells and non-metallic salt lubricant | |
US20220378790A1 (en) | Pharmaceutical preparation comprising an amide derivative inhibiting the growth of cancer cell and a pharmaceutical product containing the same | |
KR102042626B1 (ko) | 이베살탄 및 HMG-CoA 환원효소 억제제를 포함하는 약제학적 캡슐 복합제제 | |
TW202128170A (zh) | 包含抑制癌細胞生長之醯胺衍生物的藥學製備物及含有其之藥學產品 | |
JP2013103924A (ja) | 結晶性アトルバスタチンカルシウム含有錠剤の製造方法 |